Caplin Point Laboratories Ltd's Q4FY18 consolidated net profit rises 5.91% yoy to Rs35.29cr : Misses Estimates

The company’s consolidated revenue stood at Rs143.41cr, up 21.47% yoy and 1.27% qoq.

May 29, 2018 09:05 IST India Infoline Research Team

Caplin Point Laboratories Ltd Q4FY18

Consolidated Results Q4FY18: (Rs. in cr)

Q4FY18 YoY (%)
Revenue 143.41 21.5
EBITDA 48.72 12.7
EBITDA Margin (%) 34 [264]
Net Profit (adjusted) 35.29 5.9
***EBITDA margin change is bps


Reco. Price


Last updated on


For Q4FY18, Caplin Point Laboratories reported 21.5% yoy growth in the revenue to Rs143.4cr vs. Rs118.3cr in Q4FY17. EBITDA grew by 12.7% yoy to Rs48.7cr vs. Rs43.2cr in Q4FY17. EBITDA margins in Q4FY18 were at 34% vs 36.6% in Q4FY17 and 35.9% in Q3FY18. PAT grew by 5.9% yoy to Rs35.3cr vs Rs33.3cr in Q4FY17.
  • Gross margin stood at 56.6% in Q4FY18 vs 53.8% in Q3FY18 and 57.2% in Q4FY17.
  • Material cost increased by 23% yoy to Rs62.2cr during the quarter. There was ~53bps yoy increase in the material cost as percentage of sales in Q4FY18.
  • Employee cost grew by 23.8% yoy to Rs10.1cr, as percentage of sales, employee cost increased marginally by 13bps yoy.
  • Other expenses grew by 39.2% yoy to Rs22.4cr and as percentage of sales, other expenses increased by ~198bps, which led to decline in the EBITDA margins. 

Technical View:

Caplin Point Laboratories Ltd is currently trading at Rs538.05, down by 57.25 points or 9.62% from its previous closing of Rs595.30 on the BSE. The scrip opened at Rs589.20 and has touched a high and low of Rs594.70 and Rs512.70 respectively. So far 4,30,782 (NSE+BSE) shares were traded on the counter. The stock is currently trading above its 200 DMA.

Related Story